FDA-approved Therapies for Geographic Atrophy

Opinion
Video

An expert retina specialist discusses the recent FDA-approved treatments for geographic atrophy (GA) that slow disease progression and highlights key factors to consider before starting treatment.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Aviceda Therapeutics completes $207.5 million Series C financing in support of AVD-104 for geographic atrophy treatment

Aviceda Therapeutics completes $207.5 million Series C financing in support of AVD-104 for geographic atrophy treatment

Martin David Harp
January 9th 2025
Article
Spotlighting telemedicine in the year of a pandemic

Spotlighting telemedicine in the year of a pandemic

Alex Delaney-Gesing
October 19th 2020
Podcast
Galimedix Therapeutics initiates eDREAM phase 2 clinical trial in dry age-related macular degeneration

Galimedix Therapeutics initiates eDREAM phase 2 clinical trial in dry age-related macular degeneration

Martin David Harp
January 2nd 2025
Article
©Artur - stock.adobe.com

Ophthalmic safety notice: Potential fungal contamination prompts Systane Ultra PF voluntary recall

Lynda Charters;Sheryl Stevenson
December 27th 2024
Article
The human impact of geographic atrophy: Survey examines experiences and perceptions of patients living with GA

The human impact of geographic atrophy: Survey examines experiences and perceptions of patients living with GA

David Hutton
December 17th 2024
Article
Tenpoint Therapeutics and Visus Therapeutics complete merger, combining ophthalmic therapeutics portfolios

Tenpoint Therapeutics and Visus Therapeutics complete merger, combining ophthalmic therapeutics portfolios

David Hutton
December 15th 2024
Article
© 2025 MJH Life Sciences

All rights reserved.